In the treatment of adenocarcinoma of the proximal bile duct, our current strategy is to resect the tumor radically and to offer patients with unresectable tumors the chance of hepatic transplantation, if extrahepatic tumor growth is exluded. Tumor resection is performed by resection of the hilum alone or combined with partial hepatectomy. The latter procedure enables radical treatment of more advanced tumor stages and, eventually, a higher degree of radicality is achieved, and is recommended. This concept is based on our experience with 108 patients with proximal bile duct carcinoma operated on between February, 1975 and October, 1986.In |0 patients, no therapeutic or palliative surgical procedure could be performed during laparotomy because of advanced tumor stage. In 30 patients, various drainage procedures were performed. Fifty-two patients underwent resection: 25 underwent resection of the hilum only, and 27 underwent resection of the hilum combined with partial liver resection. Twenty-eight of these resections were classified as curative and 24 as palliative. Sixteen patients with unresectable tumors had hepatic transplantation. In 7 of these patients, extrahepatic tumor growth was already present at the time of liver transplantation.Median survival times were: laparotomy only, 1 month; drainage procedures, 5 months; total resection, 15 months; curative resection, 23 months; palliative resection, 7 months; liver grafting, 16 months. Seven patients are aiive up to 21 months posttransplantation. On the basis of favorable results in our more recent group of patients, liver grafting as the ultimate chance for tumor removal in patients otherwise treatable only by palliative drainage procedures may be justified.

(Ann Rheum Dis 1998;57:691-693)

The aim of this study was to determine the performance of antibodies against mutated citrullinated vimentin (anti-MCV) in comparison with antibodies to cyclic citrullinated peptides (anti-CCP) in patients with rheumatoid arthritis (RA). Serum levels of anti-MCV and anti-CCP were determined in 193 patients with RA and 332 controls, and sensitivity and specificity were calculated. In a separate analysis of 86 patients, the anti-MCV levels were compared to disease activity. Sensitivity of anti-MCV versus anti-CCP was 71.5 and 69.4%, specificity was 81.3 and 97.6%, respectively. The ROC curves showed higher specificity and an advantage of anti-CCP. In seronegative RA patients the sensitivity of anti-MCV was superior over anti-CCP. Anti-MCV positivities also occurred in systemic lupus erythematosus and Sjoegren's syndrome. In a subgroup of 86 RA patients we found a significant correlation between anti-MCV and disease activity. Anti-MCV appears to be an important marker for the diagnosis of RA, and correlates also with disease activity.

Multiple infusions of infliximab were effective and well tolerated in patients with active psoriasis and PsA.